Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Carcinoma, Hepatocellular 42Carcinoma, Renal Cell 12Neoplasms 11Liver Neoplasms 8Carcinoma 5Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Leukemia, Myeloid, Acute 3Kidney Neoplasms 3Melanoma 2Hepatoblastoma 2Vaccinia 1Thyroid Neoplasms 1Sarcoma, Myeloid 1Recurrence 1Radiotherapy 1Pancreatic Neoplasms 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Liver Diseases 1Fibrolamellar hepatocellular carcinoma 1Digestive System Neoplasms 1Digestive System Diseases 1Desmoid Tumors 1Breast Neoplasms 1Advanced Liver Cancer 1Adenocarcinoma 1

Interventions

Sorafenib 1Mitoxantrone 1Leyk 1Etoposide 1Daunorubicin 1Cytarabine 1Bortezomib 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Sarcoma, Myeloid × Sorafenib × Clear all
NCT01371981 2026-06-02

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
1,645 enrolled 32 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡